Degarelix (CAS 214766-78-6) – Research Grade is a high-purity chemical compound.

Degarelix is a polypeptide.

Research Context

Degarelix, a potent gonadotropin-releasing hormone (GnRH) antagonist, has garnered significant attention in the field of oncology, particularly in the treatment of prostate cancer. Its ability to inhibit the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) leads to a rapid decrease in testosterone levels, making it a valuable therapeutic option for hormone-sensitive malignancies.

Research Applications

Degarelix is primarily used in clinical settings to manage advanced prostate cancer. Studies have demonstrated its effectiveness in reducing testosterone levels more rapidly than traditional therapies such as LHRH agonists. Furthermore, ongoing research is exploring its potential applications in other hormone-dependent tumors, including breast and ovarian cancers. The drug is also being investigated for its efficacy in managing conditions like endometriosis and uterine fibroids, where hormonal modulation plays a crucial role.

Mechanism of Action

Degarelix functions by binding competitively to GnRH receptors in the pituitary gland, inhibiting the secretion of LH and FSH. This mechanism results in a profound suppression of gonadal steroidogenesis, effectively lowering circulating testosterone levels within days of administration. Unlike GnRH agonists, which initially cause a surge in hormone levels, Degarelix provides a rapid therapeutic effect, making it particularly advantageous in managing acute symptoms associated with advanced prostate cancer.

Solubility and Storage Advice

Degarelix is soluble in water and should be stored at controlled room temperature, away from light and moisture to maintain its stability and efficacy. It is crucial to follow proper handling guidelines to ensure the integrity of the compound, especially in research settings where precise dosing is required.

Future Research Directions

Future research on Degarelix may focus on combination therapies with other oncological agents to enhance treatment outcomes. Additionally, studies are needed to further elucidate its long-term effects and potential applications beyond prostate cancer. As researchers continue to explore the pharmacokinetics and pharmacodynamics of this drug, there is potential for significant advancements in treatment paradigms for hormone-responsive cancers.